Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Acquisitions & Divestments: 2009-2024

Historic Change in Acquisitions & Divestments for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to $863.3 million.

  • Madrigal Pharmaceuticals' Change in Acquisitions & Divestments rose 28.28% to $275.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 69.80%. This contributed to the annual value of $863.3 million for FY2024, which is 158.93% up from last year.
  • Madrigal Pharmaceuticals' Change in Acquisitions & Divestments amounted to $863.3 million in FY2024, which was up 158.93% from $333.4 million recorded in FY2023.
  • Madrigal Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $863.3 million for FY2024, and its period low was $333.4 million during FY2023.
  • Its 3-year average for Change in Acquisitions & Divestments is $515.7 million, with a median of $350.4 million in 2022.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first dropped by 24.72% in 2020, then soared by 158.93% in 2024.
  • Yearly analysis of 5 years shows Madrigal Pharmaceuticals' Change in Acquisitions & Divestments stood at $489.5 million in 2020, then dropped by 20.47% to $389.3 million in 2021, then decreased by 9.99% to $350.4 million in 2022, then declined by 4.85% to $333.4 million in 2023, then spiked by 158.93% to $863.3 million in 2024.